

Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest
and Waiver under 18 U.S.C. §208(b)(3)

Aman Buzdar, M.D.

Committees: Oncologic Drugs Advisory Committee

Meeting Date: December 5, 2007

I acknowledge that contingent upon public disclosure of the financial interests listed below, related to discussions of supplemental BLA 125085/91, Avastin (bevacizumab), Genetech, Inc., proposed indication, in combination with paclitaxel, for the treatment of patients who have not received chemotherapy for their locally recurrent or metastatic, HER2 negative breast cancer, I am eligible to receive a waiver under 18 U.S.C. §208 (b)(3).

Type of Interest	Nature	Magnitude
Employer's study of a competing product for unrelated indication	Competing firms	More than \$300,001 per year which is co-funded by 2 competing firms

I hereby request that FDA make this information publicly available on my behalf at the start of the advisory committee meeting for which it is issued by reading the statement into the record at the time of the meeting. I understand that without public disclosure of these interests the waiver is not valid.

/S/
Signature of SGE

10/30/07
Date